Australian Government
Department of Health
Therapeutic Goods Administration

Advisory Committee on Vaccines

Meeting Statement 29 – Friday 7 January 2022

Section A: Submissions for registration

The committee provided advice on one application:

- provisional registration of a new vaccine for active immunisation for COVID-19 (product name Nuvaxovid; active ingredient SARS-CoV-2 rS with Matrix-M adjuvant; applicant Biocelect Pty Ltd) that had been under evaluation from February 2021.

Details of the ACV advice associated with this pre-market item have been released within the Australian Public Assessment Report (AusPAR). To locate the AusPARs see AusPAR search.

Section B: Safety

The committee was not asked to provide advice on a safety matter.

Further information

For further information on the ACV, please visit Advisory Committee on Vaccines

or contact the ACV by email ACV@health.gov.au.